cysteinyl-leukotriene

01/01/2006 - "The contribution of the cys-LT receptors to bronchial asthma has been established by the therapeutic efficacy of biosynthetic inhibitors and selective CYSLTR1 blockers. "
07/01/2007 - "In our earlier association study, the M201V variant of the cysteinyl-leukotriene 2 receptor gene (CysLT2), located at 13q14, was implicated in atopic asthma. "
03/01/2007 - "The aim of this study was to investigate and identify the relationship between urinary cysteinyl leukotriene E(4) levels and clinical response to antileukotriene treatment in patients with asthma. "
10/15/2015 - "Effects of ONO-6950, a novel dual cysteinyl leukotriene 1 and 2 receptors antagonist, in a guinea pig model of asthma."
09/01/2012 - "Cysteinyl leukotriene receptors, old and new; implications for asthma."

11/01/2010 - "EBC Cys-LT concentration increased in all asthmatic patients post-exercise (n = 17, p = .03), with the increase significantly greater in patients developing exercise-induced bronchospasm (n = 7, p = .03), whereas no change was observed in healthy controls (p = .59). "
03/01/2008 - "No correlations were found between Cys-LT concentration and the severity of exercise-induced bronchospasm or the response to montelukast. "
11/01/1999 - "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma. "
03/01/2008 - "To compare pretreatment with albuterol versus montelukast added to the current asthma regimen for protection against exercise-induced bronchospasm in children with mild-to-moderate asthma, and to determine whether cysteinyl leukotriene (Cys-LT) concentrations measured in the exhaled breath condensate correlated with response to montelukast. "

05/01/2007 - "The numerous drugs used for allergy treatment now include the new pharmacologic category of cysteinyl leukotriene (LT) antagonists. "
12/01/2005 - "procerum failed to alter the acute allergic reaction, characterized by mast cell degranulation, oedema, and cysteinyl leukotriene release. "
03/01/2001 - "The numerous drugs used for allergy treatment now include the new pharmacological category of cysteinyl leukotriene antagonists. "
09/01/2005 - "To test whether mono- or dimeric X-ray contrast media (CM) may induce the de novo production of cysteinyl-leukotriens (cys-LT), that could contribute to allergic/allergy-like side effects. "
01/01/2013 - "Taken together, these results demonstrate for the first time that cys-LT signaling downstream of CysLT1R in MCs is differentially regulated by two distinct PKCs which modulate inflammatory signals that have significant pathobiologic implications in allergic reactions and asthma pathology. "

04/01/1997 - "Our results suggest that Cys LT may play an important role in the late-phase increase in TAR in the guinea pig model of allergic rhinitis."
04/01/1997 - "To define the role of leukotriene (LT) in allergic rhinitis, we examined the effects of a cysteinyl (Cys) LT antagonist (ONO-1078, pranlukast). "
07/01/2007 - "Cysteinyl-leukotriene levels in sputum differentiate asthma from rhinitis patients with or without bronchial hyperresponsiveness."
03/01/1998 - "In this study, we examined the clinical efficacy of specific immunotherapy and its effect on cysteinyl leukotriene releasability by blood leukocytes in house dust mite allergic subjects with asthma and allergic rhinitis. "
11/01/2013 - "The EBC cysteinyl leukotriene and 8-isoprostane levels were higher in children with asthma and allergic rhinitis than in those with asthma only and healthy children. "

10/01/2008 - "The detection of the cysteinyl leukotriene 2 receptor (CysLT(2)R) within the heart and vasculature has led to studies to investigate its role in myocardial ischemia/reperfusion injury. "
10/01/2008 - "Endothelial cysteinyl leukotriene 2 receptor expression and myocardial ischemia/reperfusion injury."
03/01/2008 - "Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury."
11/01/2013 - "Protective effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against intestinal ischemia-reperfusion injury in the rat."
10/01/2008 - "Montelukast is a selective reversible cysteinyl leukotriene receptor-1 antagonist that has been found to have protective effects against renal ischemia reperfusion injury and burn-induced oxidative injury of the skin in rats. "